UK Innovation & Science Seed Fund

NorthRow (formerly Contego) is a web-based platform that enables its users to simplify and improve the quality of risk, compliance, and anti-fraud decisions. It contains a range of features that can be used separately or in combination. It allows its users to run detailed checks on people, companies, and ID documents in order to optimize business processes, reduce risk, and help ensure compliance. The platform helps confirm identity for numerous risk factors, access multiple data sources to authenticate businesses, and verify passports, visa papers, and other documents.

Antiverse is building a world-first computational antibody drug discovery platform to predict antibody-antigen binding and provide antibody drug candidates in one day. A combination of state of the art machine learning and cell-free protein synthesis is used to predict antibodies that bind to a given antigen target with high affinity. The resulting software can then take antigen taget sequence, provided by the customer, and do a high-throughput screening of all possibilities of antibody sequences to detect the sequence that will produce a high-affinity antibody for the target. The customer will be provided with the sequence in a single day, thus reducing the time typically required for antibody therapeutics discovery by 3 to 18 months.

AgPlus Diagnostics Ltd. develops a diagnostic platform technology that delivers against the market requirements of a quantitative point of care product for use across a range of clinical applications, including human and veterinary diagnostic applications. It develops, manufactures, and supplies tests and readers. The company was formerly known as Argento Diagnostics Ltd. and changed its name to AgPlus Diagnostics Ltd. in September 2012. The company was founded in 2009 and is headquartered in Sharnbrook, United Kingdom.

Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.

Linear Diagnostics Limited (LDL) is a diagnostics company based on a novel technology that allows wide range of molecular diagnostics tests to be carried out using a simple optical system. The technology provides significant advantages over the current state of the art allowing a more rapid detection of multiple targets using a single simple reagent

Vector Photonics is a spin-out company from the University of Glasgow and is based in Glasgow, Scotland, one of the UK and world’s Optical and Photonics centres of excellence.

Tropic Biosciences UK LTD operates as a biotechnology company, which develops commercial tropical crops using advanced plant breeding and gene editing technologies. The company uses non-GMO (genetically modified organism) gene editing techniques to grow and develop these crops. The company caters to coffee and banana industries. The company was incorporated in 2016 and is headquartered in Norwich, United Kingdom.

Nemesis Bioscience Ltd. develops and commercializes therapeutic agents that resurrect the antibiotic sensitivity of currently resistant microbial pathogens. Its symbiotics kill pathogenic microorganisms directly and/or make them susceptible to currently existing antibiotics. The company’s solutions are used to treat infections and to prophylactically prevent patients acquiring potentially life-threatening resistant pathogens. Nemesis Bioscience Ltd. was founded in 2014 and is based in Cambridge, United Kingdom.

MIRICO Ltd. is a UK-based laser spectroscopy instrumentation company formed in 2015 as a spin-out from the Science and Technology Facilities Council. The technology underpinning MIRICO was developed by the RAL Space Laser Spectroscopy Team, led by Dr. Damien Weidmann. The laser spectroscopy team consists of 8 senior scientists who carry out cutting edge research and development. Over the years they have developed a range of spectroscopy techniques that overcome the major downfalls of current technologies. The company was formed to commercialise and take these technologies to market.

Oxford Space Systems Limited develops, manufactures, and markets deployable hardware structures for space environments in Europe and internationally. The company develops deployable panels/hinge systems, composite linear boom systems, and deployable antennas. Oxford Space Systems Limited was incorporated in 2013 and is based in Harwell, United Kingdom.

MIRICO Ltd. is a UK-based laser spectroscopy instrumentation company formed in 2015 as a spin-out from the Science and Technology Facilities Council. The technology underpinning MIRICO was developed by the RAL Space Laser Spectroscopy Team, led by Dr. Damien Weidmann. The laser spectroscopy team consists of 8 senior scientists who carry out cutting edge research and development. Over the years they have developed a range of spectroscopy techniques that overcome the major downfalls of current technologies. The company was formed to commercialise and take these technologies to market.

Procarta Biosystems Ltd develops antibacterials through an adaptable DNA-based platform for clinics. It provides snare, a set of proprietary nanoparticles that deliver an oligonucleotide inside the bacterial pathogen, including MRSA snare, a topical and intravenous solution; Broad-spectrum Gram-negative therapy snare, which treats hospital acquired infections; and Cdiff snare, which prevents recurrence of CDI. The company was founded in 2007 and is based in Norwich, United Kingdom.

Jupiter Diagnostics offers a faster, cheaper way to obtain accurate blood tests. Our patent- protected reader can replace the lab, delivering multiple tests in 10 minutes, from a prick of blood, at prices a third cheaper.

CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation of advanced therapies. We are a spinout company from the University of Bristol. Our novel cell membrane augmentation technology enables us to add new functionalities to cell therapies including tissue specific targeting and enhanced cell survivability. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer, heart disease, osteoarthritis and diabetic wound healing. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health.

Q5D manufactures tools to automate the production of wiring harness for all industrial sectors.

MicroVisk Limited develops CoagMax, a point-of-care PT/INR monitor that provides home patient testing for an INR blood test. The company was founded in 2004 and is based in Oxford, United Kingdom.

Alopa is a pioneer and leader in the design, development, and deployment of infrastructure software solutions for end-to-end activation, management, and assurance of digital services over cable. Alopa Networks has been an industry driver in developing operations support software (OSS) solutions for broadband service providers that accelerate time-to-market for advanced network-based services and applications, including Internet telephone (VoIP), differentiated access, security, multimedia, and more. Alopa's combined family of products automates the complete life cycle of subscriber acquisition and service management by facilitating service creation, deployment, and assurance and security functions while, at the same time, accelerating revenue and lowering operating and capital expenses. Its flagship Alopa MetaServ(TM) platform is currently the only industry solution that automates the entire subscriber life cycle -- from equipment qualification through service creation and activation to customer support -- and integrates all layers of the IT infrastructure, including billing, order entry, customer care, and network management. It also provides secure provisioning for both PacketCable(TM) and CableHome(TM) networks, offering a framework for VoIP, multimedia services, and interactive gaming.

Leveraging the extensive knowledge of GSK's Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to build an infectious disease therapeutic pipeline.

Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.

They are a microbiological services provider that provide our clients with a research based approach to microbiological testing, whilst recognising the client’s need for a rapid turnaround and a personalised service. We specialise in bespoke assays with a primary focus on biofilm testing. They appreciate that not all products are appropriate for standard testing assays and therefore we work closely with our clients to develop methods that are suitable for the testing of novel products. They offer an extremely customer focused service that includes regular feedback, consultancy, method development and report writing. In addition we produce conference abstracts and posters based on the data we produce.

Tokamak Solutions UK Ltd. engages in providing technology for fusion neutron source to transmute nuclear waste. The company was founded in 2009 and is based in Abingdon, United Kingdom.

Keit’s microFTS® design is a Fourier Transform Infrared (FTIR) spectrometer that is smaller, lighter and more rugged than any current system. Able to perform in extreme environments, the microFTS® was originally designed for space applications where these attributes are paramount. The microFTS® offers a new gold standard for real-time liquid-state analyses in the Pharmaceutical, Chemical, Oil & Gas, and Food & Beverage industries.

Synthace's goal is to raise universal bioscience productivity, enabling people to better engineer biology for health, food, energy and manufacturing. Central to its technology is Antha, an operating system for biology that enables ease of designing and optimizing biological unit operations that are linked into executable workflows that are reliable, shareable and saleable. Antha spreads biological information in a repeatable way, linking lab equipment, protocols and processes, thereby allowing vast and speedy development, enhancing productivity for any bioscience.

SFH Oxford Ltd. develops and markets Graducheck, a sensor-based technology for improving the application of compression bandages for treatment of venous leg ulcers a chronic wounds for both patients and national healthcare systems. Its products include anatomic focus technology (AFT) graduated compression socks, to provide necessary levels of graduated compression; and K-gel, wound dressing. The company was founded in 2011 and is based in Didcot, United Kingdom.

NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy, safety, and economy.

Tokamak Energy Ltd manufactures a fusion power device. The company’s products ST25 and ST40 are high-temperature superconductors designed for fusion energy research. Tokamak Energy Ltd was incorporated in 2009 and is based in Abingdon, United Kingdom.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

MicrofluidX Ltd develops a cell bioprocessing platform for autologous cell and gene therapy manufacturing. The company provides a microfluidic bioprocessing system that combines multiple cell culture capabilities, such as seeding, expansion, differentiation, transduction, washing, sorting, concentration, sampling, and harvesting in one closed system. Its automated and closed technology allows biologists to carry out process development by running dozens of cell culture conditions. The company was incorporated in 2018 and is based in London, United Kingdom.

CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga. The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.

P2i is the world leader in liquid repellent nano-coating technology. The company’s revolutionary plasma process reduces the surface energy of a material so that when liquids come into contact with it, they form beads and simply roll off. P2i’s customers can improve the performance of their products by protecting them from the effects of water and other liquids without affecting their look or feel. P2i’s plasma processing machines have been sold into the textile, consumer electronics, filtration, and bioconsumables markets.

CHAIN Biotechnology is a microbiome therapeutics company with a novel drug development platform targeting chronic gut-related diseases. CHAIN is developing several therapeutic compounds targeted to the gut microbiome in the large intestine that can be delivered by our CADD technology.

Ikarovec is developing novel gene therapies to treat major ophthalmic indications.

Pencil Biosciences aims to develop a novel, programmable genome-modulation tool that overcomes the challenges associated with the technologies currently available.

MicroVisk Limited develops CoagMax, a point-of-care PT/INR monitor that provides home patient testing for an INR blood test. The company was founded in 2004 and is based in Oxford, United Kingdom.

MicroVisk Limited develops CoagMax, a point-of-care PT/INR monitor that provides home patient testing for an INR blood test. The company was founded in 2004 and is based in Oxford, United Kingdom.

Oxsensis Ltd. produces non-electrical sensor systems that enable measurements to be made at the extremes of electromagnetic interference and temperature. The company offers optical pressure sensor systems for real-time measurement of dynamic pressure sensor systems, dynamic and static pressure with temperature, and static pressure sensor systems; temperature transducers; and optical accelerometers. Its products are used in aerospace, power generation, oil and gas, reciprocating engine, space, and nuclear industries. The company was founded in 2003 and is based in Didcot, United Kingdom. It has additional offices in the United States, Russia, China, and Japan.

Atelerix Limited provides storage and transportation of cells and tissues at room temperature. The company provides suspended cells, planted cells, and tissues. It also discovers and tests new drugs, develops cell therapies, and stores stem cells. The company was founded in 2006 and is based in Cambridge, United Kingdom.

Procarta Biosystems Ltd develops antibacterials through an adaptable DNA-based platform for clinics. It provides snare, a set of proprietary nanoparticles that deliver an oligonucleotide inside the bacterial pathogen, including MRSA snare, a topical and intravenous solution; Broad-spectrum Gram-negative therapy snare, which treats hospital acquired infections; and Cdiff snare, which prevents recurrence of CDI. The company was founded in 2007 and is based in Norwich, United Kingdom.

Glialign is developing a novel cell therapy for peripheral nerve repair — for which current therapies are only successful in less than half of the cases and often can require grafting of a nerve from another part of the body.

CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation of advanced therapies. We are a spinout company from the University of Bristol. Our novel cell membrane augmentation technology enables us to add new functionalities to cell therapies including tissue specific targeting and enhanced cell survivability. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer, heart disease, osteoarthritis and diabetic wound healing. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health.

NorthRow (formerly Contego) is a web-based platform that enables its users to simplify and improve the quality of risk, compliance, and anti-fraud decisions. It contains a range of features that can be used separately or in combination. It allows its users to run detailed checks on people, companies, and ID documents in order to optimize business processes, reduce risk, and help ensure compliance. The platform helps confirm identity for numerous risk factors, access multiple data sources to authenticate businesses, and verify passports, visa papers, and other documents.

Agilent Raman Spectroscopy’s proprietary technologies use novel variants of Raman spectroscopy. Their instruments can rapidly and accurately identify materials hidden inside objects or through opaque barriers such as plastic, coloured glass, paper and skin, or can measure the concentrations of materials in mixtures, with a high degree of accuracy. Agilent Raman Spectroscopy is formerly known as Cobalt Light Systems and is part of Agilent.

Life sciences smart data management and analysis solutions

Linear Diagnostics Limited (LDL) is a diagnostics company based on a novel technology that allows wide range of molecular diagnostics tests to be carried out using a simple optical system. The technology provides significant advantages over the current state of the art allowing a more rapid detection of multiple targets using a single simple reagent

Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases. Our initial focus is on developing therapies to reduce progressive visual loss in glaucoma and other conditions affecting the optic nerve. Quethera is working alongside world leaders in the glaucoma field to design clinical trials capable of examining the efficacy and safety of novel therapies in patients who lose parts of their visual field at an accelerated rate (fast-progressors). The company has expertise in gene therapeutic design and development sufficient to progress its pipeline through preclinical testing and into clinical development.

The Electrospinning Company is a leading edge provider of electrospun nanofibre innovations, developing solutions to industrial challenges. They also work closely with academic research groups to develop novel nano-scale fibres and coatings for scientific research.

Claresys develops and supplies lens solutions for covert surveillance. Its products include covert pinhole pan/tilt/zoom lenses for mounting on C mount 1/3” sensor cameras; and miniature pinhole camera lenses. The company also designs custom lens for long range surveillance and difficult environments, such as nuclear and high temperature fields. Its optical technologies are applied in various surveillance situations, including close surveillance in buildings and vehicles, and long distance stake-outs.

Cytox have developed a simple genetic based blood test for the assessment of risk and diagnosis of Alzheimer's Disease in the very early stages. Alzheimer's Disease affects over 26 million people world-wide and is a growing condition as people live longer. There is currently no cure for Alzheimer's Disease, but there are large international initiatives underway to find treatments with many drugs in clinical development. Cytox are commercially launching their tests in conjunction with Affymetrix (part of Thermo Fisher Scientific) to support Pharmaceutical and Biotechnology companies developing novel therapeutics.

Atelerix Limited provides storage and transportation of cells and tissues at room temperature. The company provides suspended cells, planted cells, and tissues. It also discovers and tests new drugs, develops cell therapies, and stores stem cells. The company was founded in 2006 and is based in Cambridge, United Kingdom.

CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga. The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.

Microbial Solutions Limited offers a technology that can provide on-site treatment and disposal of MWFs which can unlock and release the replacement value of both the existing treatment technology and the associated logistics costs. The Microcycle™ technology is a powerful, patented biological degradation process that reduces waste MWFs to acceptable COD concentrations, removes toxicity and allows for the safe disposal of MWF as grey water to sewers on site. Through their offering, Microbial Solutions seeks to help their clients to cost-effectively meet their environmental responsibilities and to provide regulators with the tools to implement the regulations enshrining those responsibilities.

Procarta Biosystems Ltd develops antibacterials through an adaptable DNA-based platform for clinics. It provides snare, a set of proprietary nanoparticles that deliver an oligonucleotide inside the bacterial pathogen, including MRSA snare, a topical and intravenous solution; Broad-spectrum Gram-negative therapy snare, which treats hospital acquired infections; and Cdiff snare, which prevents recurrence of CDI. The company was founded in 2007 and is based in Norwich, United Kingdom.

Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by the real-world impact of CRISPR technology. They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive.

They are a microbiological services provider that provide our clients with a research based approach to microbiological testing, whilst recognising the client’s need for a rapid turnaround and a personalised service. We specialise in bespoke assays with a primary focus on biofilm testing. They appreciate that not all products are appropriate for standard testing assays and therefore we work closely with our clients to develop methods that are suitable for the testing of novel products. They offer an extremely customer focused service that includes regular feedback, consultancy, method development and report writing. In addition we produce conference abstracts and posters based on the data we produce.

Life sciences smart data management and analysis solutions

Procarta Biosystems Ltd develops antibacterials through an adaptable DNA-based platform for clinics. It provides snare, a set of proprietary nanoparticles that deliver an oligonucleotide inside the bacterial pathogen, including MRSA snare, a topical and intravenous solution; Broad-spectrum Gram-negative therapy snare, which treats hospital acquired infections; and Cdiff snare, which prevents recurrence of CDI. The company was founded in 2007 and is based in Norwich, United Kingdom.

CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation of advanced therapies. We are a spinout company from the University of Bristol. Our novel cell membrane augmentation technology enables us to add new functionalities to cell therapies including tissue specific targeting and enhanced cell survivability. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer, heart disease, osteoarthritis and diabetic wound healing. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health.

CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga. The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.

Synthace's goal is to raise universal bioscience productivity, enabling people to better engineer biology for health, food, energy and manufacturing. Central to its technology is Antha, an operating system for biology that enables ease of designing and optimizing biological unit operations that are linked into executable workflows that are reliable, shareable and saleable. Antha spreads biological information in a repeatable way, linking lab equipment, protocols and processes, thereby allowing vast and speedy development, enhancing productivity for any bioscience.

Antiverse is building a world-first computational antibody drug discovery platform to predict antibody-antigen binding and provide antibody drug candidates in one day. A combination of state of the art machine learning and cell-free protein synthesis is used to predict antibodies that bind to a given antigen target with high affinity. The resulting software can then take antigen taget sequence, provided by the customer, and do a high-throughput screening of all possibilities of antibody sequences to detect the sequence that will produce a high-affinity antibody for the target. The customer will be provided with the sequence in a single day, thus reducing the time typically required for antibody therapeutics discovery by 3 to 18 months.

Spectral Edge combines patented Image Fusion tech with Deep Learning to reveal more of the color, detail and clarity in any image.

MIRICO Ltd. is a UK-based laser spectroscopy instrumentation company formed in 2015 as a spin-out from the Science and Technology Facilities Council. The technology underpinning MIRICO was developed by the RAL Space Laser Spectroscopy Team, led by Dr. Damien Weidmann. The laser spectroscopy team consists of 8 senior scientists who carry out cutting edge research and development. Over the years they have developed a range of spectroscopy techniques that overcome the major downfalls of current technologies. The company was formed to commercialise and take these technologies to market.

Puraffinity was incorporated in 2015 and is headquartered in London. The company specialises in the design of advanced materials, and has developed a bio-based novel adsorbent capable of removing highly challenging pollutants from contaminated water and wastewater. The technology utilises advanced supramolecular chemistry methods to functionalise bio-based materials designed to bind target chemicals. The company is at the forefront of developing solutions for overcoming imminent water quality challenges, whilst sustainable and positive environmental impact lies at the heart of the company’s ethos.

Atelerix Limited provides storage and transportation of cells and tissues at room temperature. The company provides suspended cells, planted cells, and tissues. It also discovers and tests new drugs, develops cell therapies, and stores stem cells. The company was founded in 2006 and is based in Cambridge, United Kingdom.

Orbital Optics is engages in the sale of space optical cameras for space missions in the United Kingdom and internationally. It also provides consultancy on matters concerned with imaging systems and optical payloads, as well as access to supporting ground station facilities.

Tropic Biosciences UK LTD operates as a biotechnology company, which develops commercial tropical crops using advanced plant breeding and gene editing technologies. The company uses non-GMO (genetically modified organism) gene editing techniques to grow and develop these crops. The company caters to coffee and banana industries. The company was incorporated in 2016 and is headquartered in Norwich, United Kingdom.

Cagen is a synthetic biology company.

Camstech Ltd is an early stage company developing novel biochemical sensing technologies. Having graduated from the CERN Business Incubation Centre at Harwell Campus in Oxfordshire, the company is now based at STFC’s Campus Technology Hub, Daresbury Laboratory. Camstech was established in 2014 with a vision to commercialise a novel sensing technology developed by Professor Pankaj Vadgama, initially for life sciences research and subsequently for applications in biotechnology and medical diagnostics.

The problem of Needle Stick Injuries (NSI's) is well known throughout medical practice worldwide. However despite nearly two decades of work and legislation in the USA, Europe and other countries, the incidents of NSI's have not fallen as fast or as far as was hoped C-Major Medical was established with the sole purpose of developing a new range of safety devices that will enable, hospitals, clinics and medical practicioners everywhere to prevent NSI's.

MyoDOPA is develops a novel therapeutic profile providing efficient treatment.

Pireta Ltd develops and commercializes technology to produce smart textiles. It develops an additive process that adds conductivity and sensors to fabrics at any stage of manufacturing without affecting fabrics’ handle and drape. The fabric produced by the company's technology are used for communication, measurement of physiological changes, and tracking. The company develops smart textiles for the military, emergency services and defense, fashion, athletes and elite sport, healthcare, bio science, and RFID tagging industries. Pireta Ltd was founded in 2017 and is based in Teddington, United Kingdom.

NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy, safety, and economy.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Life sciences smart data management and analysis solutions

SFH Oxford Ltd. develops and markets Graducheck, a sensor-based technology for improving the application of compression bandages for treatment of venous leg ulcers a chronic wounds for both patients and national healthcare systems. Its products include anatomic focus technology (AFT) graduated compression socks, to provide necessary levels of graduated compression; and K-gel, wound dressing. The company was founded in 2011 and is based in Didcot, United Kingdom.

Synthace's goal is to raise universal bioscience productivity, enabling people to better engineer biology for health, food, energy and manufacturing. Central to its technology is Antha, an operating system for biology that enables ease of designing and optimizing biological unit operations that are linked into executable workflows that are reliable, shareable and saleable. Antha spreads biological information in a repeatable way, linking lab equipment, protocols and processes, thereby allowing vast and speedy development, enhancing productivity for any bioscience.

The problem of Needle Stick Injuries (NSI's) is well known throughout medical practice worldwide. However despite nearly two decades of work and legislation in the USA, Europe and other countries, the incidents of NSI's have not fallen as fast or as far as was hoped C-Major Medical was established with the sole purpose of developing a new range of safety devices that will enable, hospitals, clinics and medical practicioners everywhere to prevent NSI's.

AgPlus Diagnostics Ltd. develops a diagnostic platform technology that delivers against the market requirements of a quantitative point of care product for use across a range of clinical applications, including human and veterinary diagnostic applications. It develops, manufactures, and supplies tests and readers. The company was formerly known as Argento Diagnostics Ltd. and changed its name to AgPlus Diagnostics Ltd. in September 2012. The company was founded in 2009 and is headquartered in Sharnbrook, United Kingdom.

Tropic Biosciences UK LTD operates as a biotechnology company, which develops commercial tropical crops using advanced plant breeding and gene editing technologies. The company uses non-GMO (genetically modified organism) gene editing techniques to grow and develop these crops. The company caters to coffee and banana industries. The company was incorporated in 2016 and is headquartered in Norwich, United Kingdom.